The United Kingdom and the United States have announced a important commercial pact that will guarantee zero levies on British pharmaceutical exports going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to boost spending on drugs through the NHS. This move ensures that import taxes on these key exports will stay at zero for a duration of 36 months.
This development is in response to earlier statements to hike duties on branded drug products, with figures discussed up to 100%.
"This agreement between the United Kingdom bolsters the global environment for new treatments and introduces much-needed equity to American-British medicine commerce," a statement noted.
Economic Importance
Medicines constitute one of the UK's largest goods shipped to the US, which is clearly the biggest market for major UK drugmakers.
Export figures reveal that in the 12 months to the end of last September, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This value accounted for a significant portion of British export trade in that timeframe.
"This deal secures employment, increases capital expenditure and facilitates the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Detailed UK Commitments
The agreement involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to raise overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The amount drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, rebates were more than 20%.
Recent Tensions
This agreement follows a protracted row between the drug companies and the ministers over drug pricing and NHS adoption.
This friction were heightened by claims that American patients were charged significantly more for the equivalent treatments than consumers in the other developed nations.
In recent months, several major drug company projects in the UK have been halted or scrapped, while major funding commitments have been directed toward American operations.
One official stated that the NHS had to increase expenditure on treatments, noting that its spending on drugs had shrunk as a share of its total funding over the previous ten-year period.
